• How do recent systemic approvals influence treatment selection for patients with psoriatic disease?​

  • 2024/08/09
  • 再生時間： 25 分
  • ポッドキャスト

How do recent systemic approvals influence treatment selection for patients with psoriatic disease?​

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • During the Psoriasis Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current treatment landscape for patients with psoriasis and PsA.

    The recorded discussion was chaired by Paolo Gisondi, and featured Alice Gottlieb and Yukari Okubo. The steering committee discussed recent approvals of systemic agents for psoriatic disease, including efficacy and safety data of bimekizumab and deucravacitinib. They also spoke about how to avoid and treat oral candidiasis infections in patients treated with interleukin 17 inhibitors.


    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示

あらすじ・解説

During the Psoriasis Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current treatment landscape for patients with psoriasis and PsA.

The recorded discussion was chaired by Paolo Gisondi, and featured Alice Gottlieb and Yukari Okubo. The steering committee discussed recent approvals of systemic agents for psoriatic disease, including efficacy and safety data of bimekizumab and deucravacitinib. They also spoke about how to avoid and treat oral candidiasis infections in patients treated with interleukin 17 inhibitors.


Hosted on Acast. See acast.com/privacy for more information.
続きを読む 一部表示

How do recent systemic approvals influence treatment selection for patients with psoriatic disease?​に寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。